Anthropic Taps Twist Bioscience to Validate Claude's Drug Design, Stock Surges 17%
TWST has more than doubled off its 52-week low of $23.3.
Summary
Anthropic selected Twist Bioscience as an independent evaluator to test whether its Claude AI model can accelerate drug design. Twist independently produced and tested Claude's minibinder designs in the lab, finding success on 14 of 15 protein targets. The stock jumped 17% to $136.41, on track for its highest close since 2021, and has more than quadrupled year to date. This validates Twist's synthetic biology platform for AI-driven drug discovery and could open a new revenue stream. The partnership follows a $300M upsized offering priced at $96 on August 5, showing strong investor demand. Watch for further collaboration announcements or revenue impact from AI-related services.
At the time of this announcement, TWST was trading at $136.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9B. The 52-week trading range was $23.30 to $141.10. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.